ForCast Orthopedics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ForCast Orthopedics is a private, pre-revenue company founded in 2018 and based in San Diego, CA, USA, focused on transforming the treatment of periprosthetic joint infection (PJI). The company is developing a targeted antibiotic infusion therapy platform designed to combat biofilm-protected bacteria on orthopedic implants. Key milestones include FDA QIDP designations for its pipeline programs and a strategic partnership with KORU Medical Systems for its infusion delivery technology. ForCast is building a strong scientific advisory board with recognized leaders in orthopedic infection to guide its clinical development.

Periprosthetic Joint InfectionOrthopedic Infections

Technology Platform

Targeted antibiotic infusion therapy platform utilizing a partnered portable infusion system (KORU FreedomEDGE®) for local, sustained delivery of antibiotics to combat biofilm on orthopedic implants.

Opportunities

The growing volume of joint replacement surgeries creates a larger addressable population for PJI treatment.

The high economic and human cost of current PJI management presents a compelling value proposition for a targeted therapy that can reduce revision surgeries and improve outcomes.

FDA QIDP designation provides a faster regulatory pathway and potential market exclusivity.

Risk Factors

High clinical development risk, as the novel therapy must prove safety and efficacy in challenging PJI cases.

Regulatory and reimbursement hurdles remain significant despite QIDP status.

Market adoption requires changing the entrenched surgical standard of care among orthopedic surgeons.

Competitive Landscape

Competition includes the entrenched standard of care (surgical debridement/explanation & systemic antibiotics) and other local delivery methods like antibiotic-loaded bone cement and spacers. Other companies may be developing similar targeted infusion or biofilm-disrupting technologies, but ForCast's specific platform and QIDP designations provide differentiation.

More companies in Small Molecule Drugs →More companies in United States →